Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama(Eisai (Japan)), Yasuhiro Funahashi(Eisai (Japan))
Cited by 479
Related Papers
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
|Cancer Science|2017|65
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
|Scientific Reports|2020|59